Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

296.04USD
22 Jun 2018
Change (% chg)

$-1.30 (-0.44%)
Prev Close
$297.34
Open
$298.00
Day's High
$298.38
Day's Low
$295.22
Volume
659,766
Avg. Vol
673,660
52-wk High
$370.53
52-wk Low
$249.24

Select another date:

Thu, May 17 2018

Samsung BioLogics said JV partner Biogen to exercise option by late June

SEOUL, May 18 Samsung BioLogics said on Friday that its joint venture partner Biogen would exercise its call option to increase its stake to 50 pct minus one share in Samsung Bioepis.

BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab

* BIOGEN AND NEURIMMUNE ANNOUNCE OPTION EXERCISE FOR ALZHEIMER'S DISEASE INVESTIGATIONAL TREATMENT ADUCANUMAB

BRIEF-Biogen CEO Michel Vounatsos' Total Compensation For 2017 Was $13.7 Million

* BIOGEN SAYS CEO MICHEL VOUNATSOS' TOTAL COMPENSATION FOR 2017 WAS $13.7 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2KjjpbG) Further company coverage:

Biogen's revenue misses as Spinraza sales disappoint

Drugmaker Biogen Inc's quarterly revenue missed analysts' estimates on Tuesday as it had disappointing sales of its promising drug Spinraza to treat spinal muscular atrophy because fewer new patients used the expensive treatment.

UPDATE 3-Biogen's revenue misses as Spinraza sales disappoint

* Biogen shares pare losses (Adds conference call, analysts comments; updates shares)

Biogen quarterly profit jumps on higher Spinraza sales

April 24 Drug developer Biogen Inc reported a 57 percent jump in quarterly profit on Tuesday, helped by higher sales of its spinal muscular atrophy drug, Spinraza.

BRIEF-Biogen Reports Quarterly Revenues Of $3.1 Billion

* QTRLY SPINRAZA REVENUE OF $364 MILLION VERSUS $47 MILLION REPORTED LAST YEAR

Biogen boosts investment in neurology with $1 billion Ionis deal

Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.

BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

* BIOGEN AND IONIS EXPAND STRATEGIC COLLABORATION TO DEVELOP DRUG CANDIDATES FOR A BROAD RANGE OF NEUROLOGICAL DISEASES

UPDATE 2-Biogen boosts investment in neurology with $1 bln Ionis deal

* Comprises equity investment in Ionis plus upfront payment (Adds background, share movement)

Select another date: